Unknown

Dataset Information

0

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.


ABSTRACT: Among 242 Japanese pancreatic cancer patients, three patients (1.2%) encountered life-threatening toxicities, including myelosuppression, after gemcitabine-based chemotherapies. Two of them carried homozygous CDA*3 (CDA208G>A [Ala70Thr]), and showed extremely low plasma cytidine deaminase activity and gemcitabine clearance. Our results suggest that homozygous *3 is a major factor causing gemcitabine-mediated severe adverse reactions among the Japanese population.

SUBMITTER: Ueno H 

PROVIDER: S-EPMC2661788 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.

Ueno H H   Kaniwa N N   Okusaka T T   Ikeda M M   Morizane C C   Kondo S S   Sugiyama E E   Kim S R SR   Hasegawa R R   Saito Y Y   Yoshida T T   Saijo N N   Sawada J J  

British journal of cancer 20090301 6


Among 242 Japanese pancreatic cancer patients, three patients (1.2%) encountered life-threatening toxicities, including myelosuppression, after gemcitabine-based chemotherapies. Two of them carried homozygous CDA*3 (CDA208G>A [Ala70Thr]), and showed extremely low plasma cytidine deaminase activity and gemcitabine clearance. Our results suggest that homozygous *3 is a major factor causing gemcitabine-mediated severe adverse reactions among the Japanese population. ...[more]

Similar Datasets

| S-EPMC3067724 | biostudies-literature
| S-EPMC9303231 | biostudies-literature
| S-EPMC5846100 | biostudies-literature
| S-EPMC10645818 | biostudies-literature
| S-EPMC8616255 | biostudies-literature
| S-EPMC8640838 | biostudies-literature
| S-EPMC6987424 | biostudies-literature
| S-EPMC6049660 | biostudies-literature
| S-EPMC10692844 | biostudies-literature
| S-EPMC7132983 | biostudies-literature